Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019.
Economic burden
Iran
Medication costs
Multiple sclerosis (MS)
Journal
Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
17
07
2021
accepted:
20
10
2021
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
ppublish
Résumé
Due to the invariably progressive nature of multiple sclerosis (MS) and the high economic burden of chronic diseases, this study was performed to estimate the economic burden of MS medications in Iran. The present research is a descriptive study performed using comprehensive national data of Iran's Health Insurance Organization (IHIO). The timeframe for study was 2011-2019. In order to calculate the economic burden of MS medications, the cost of illness (COI) method based on the prevalence approach was used. In this study, economic burden estimation was performed according to available data on medication costs. Data mining was also used to perform different stages of study. The number of patients receiving MS medications covered by IHIO has increased from 19,367 in 2011 to 50,642 in 2019. The economic burden of MS medications of patients covered by the IHIO increased from $81 million to $96 million between 2011 and 2019, respectively. Among the 9 medications studied, Interferon accounted for a very high share of costs in all years. The cost per patient receiving medication has also increased from $7,000 in 2011 to $18,000 in 2019. Calculations of the economic burden of MS medications in Iran showed an upward trend during the 9 years of the study, which due to the increasing number of patients in Iran, the arrival of new medications and also the increase in prices.
Sections du résumé
Background
UNASSIGNED
Due to the invariably progressive nature of multiple sclerosis (MS) and the high economic burden of chronic diseases, this study was performed to estimate the economic burden of MS medications in Iran.
Methods
UNASSIGNED
The present research is a descriptive study performed using comprehensive national data of Iran's Health Insurance Organization (IHIO). The timeframe for study was 2011-2019. In order to calculate the economic burden of MS medications, the cost of illness (COI) method based on the prevalence approach was used. In this study, economic burden estimation was performed according to available data on medication costs. Data mining was also used to perform different stages of study.
Results
UNASSIGNED
The number of patients receiving MS medications covered by IHIO has increased from 19,367 in 2011 to 50,642 in 2019. The economic burden of MS medications of patients covered by the IHIO increased from $81 million to $96 million between 2011 and 2019, respectively. Among the 9 medications studied, Interferon accounted for a very high share of costs in all years. The cost per patient receiving medication has also increased from $7,000 in 2011 to $18,000 in 2019.
Conclusion
UNASSIGNED
Calculations of the economic burden of MS medications in Iran showed an upward trend during the 9 years of the study, which due to the increasing number of patients in Iran, the arrival of new medications and also the increase in prices.
Identifiants
pubmed: 37089141
doi: 10.18502/ijph.v52i2.11894
pii: IJPH-52-407
pmc: PMC10113575
doi:
Types de publication
Journal Article
Langues
eng
Pagination
407-419Informations de copyright
Copyright © 2023 Asadollahi et al. Published by Tehran University of Medical Sciences.
Déclaration de conflit d'intérêts
Conflict of interests The authors have declared that no competing interests exist
Références
BMJ Support Palliat Care. 2018 Mar;8(1):38-40
pubmed: 28647714
Mult Scler Relat Disord. 2020 Sep;44:102247
pubmed: 32554286
Health Econ Rev. 2012 Sep 11;2(1):18
pubmed: 22963680
Int Rev Neurobiol. 2007;79:357-75
pubmed: 17531850
Am J Manag Care. 2016 Jun;22(6 Suppl):s151-8
pubmed: 27356024
J Clin Neurosci. 2017 Nov;45:180-186
pubmed: 28676312
Eur J Health Econ. 2018 Dec;19(9):1243-1257
pubmed: 29680926
PLoS One. 2019 May 14;14(5):e0216646
pubmed: 31086393
Neurol Sci. 2015 Feb;36(2):227-34
pubmed: 25109816
Pharmacoeconomics. 2010;28(5):363-79
pubmed: 20402540
Mult Scler. 2010 Mar;16(3):359-61
pubmed: 20086021
Mult Scler Relat Disord. 2019 Nov;36:101396
pubmed: 31525627
Neurotherapeutics. 2017 Oct;14(4):1018-1026
pubmed: 28812229
Mult Scler. 2010 Dec;16(12):1525-6
pubmed: 20534643
Health Promot Chronic Dis Prev Can. 2017 Feb;37(2):37-48
pubmed: 28273039
BMC Neurol. 2020 May 23;20(1):205
pubmed: 32446303
Mult Scler Relat Disord. 2020 Aug;43:102162
pubmed: 32442885